71.70

0.38% -0.27

Ptc Therapeutics Inc (PTCT)

Overview News Price History Option Chain Financials Why PTCT Down? Discussions Forecast

Ptc Therapeutics Inc stock is traded at $71.70, with a volume of 564.33K. It is down -0.38% in the last 24 hours and down -8.15% over the past month. PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.

Previous Close:

$71.97

Open:

$71.58

24h Volume:

564.33K

Relative Volume:

0.33

Market Cap:

$5.98B

Revenue:

$1.73B

Net Income/Loss:

$682.64M

P/E Ratio:

9.2679

EPS:

7.7364

Net Cash Flow:

$411.18M

1W Performance:

-2.20%

1M Performance:

-8.15%

6M Performance:

+3.24%

1Y Performance:

+47.23%

1-Day Range:

$70.85

$72.13

1-Week Range:

$70.85

$75.00

52-Week Range:

$47.94

$90.87

Ptc Therapeutics Inc Stock (PTCT) Company Profile

Name

Ptc Therapeutics Inc

Sector

Healthcare (1080)

Industry

Biotechnology (604)

Phone

(908) 222-7000

Address

500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ

Employee

991

Twitter

@PTCBio

Next Earnings Date

2026-07-30

Latest SEC Filings

PTCT's Discussions on Twitter

Compare PTCT vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PTCT Ptc Therapeutics Inc	71.70	6.06B	1.73B	682.64M	411.18M	7.7364
VRTX Vertex Pharmaceuticals Inc	505.75	133.25B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	803.48	82.16B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	851.29	54.80B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	203.71	43.99B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	347.48	40.62B	5.76B	514.49M	1.10B	4.4813

Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-10-26	Initiated	Raymond James	Outperform
Jan-28-26	Resumed	Barclays	Overweight
Dec-01-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Oct-20-25	Initiated	Wells Fargo	Overweight
Jun-17-25	Initiated	Truist	Buy
May-09-25	Upgrade	BofA Securities	Neutral → Buy
May-07-25	Upgrade	Citigroup	Sell → Neutral
Mar-11-25	Upgrade	BofA Securities	Underperform → Neutral
Mar-07-25	Initiated	Scotiabank	Sector Perform
Dec-13-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Dec-03-24	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Oct-10-24	Resumed	Raymond James	Mkt Perform
Sep-04-24	Initiated	Robert W. Baird	Outperform
Aug-26-24	Resumed	UBS	Buy
May-20-24	Upgrade	Raymond James	Underperform → Mkt Perform
Dec-19-23	Downgrade	Morgan Stanley	Equal-Weight → Underweight
Dec-08-23	Initiated	Wells Fargo	Overweight
Oct-30-23	Upgrade	Oppenheimer	Perform → Outperform
Oct-27-23	Downgrade	Citigroup	Neutral → Sell
Oct-06-23	Downgrade	Truist	Buy → Hold
Sep-18-23	Downgrade	Citigroup	Buy → Neutral
Sep-15-23	Downgrade	Raymond James	Outperform → Underperform
Mar-17-23	Initiated	SVB Securities	Market Perform
Dec-14-22	Initiated	Goldman	Sell
Sep-12-22	Initiated	Jefferies	Buy
Sep-09-22	Initiated	Morgan Stanley	Equal-Weight
Sep-01-22	Initiated	Citigroup	Buy
Apr-04-22	Resumed	Cantor Fitzgerald	Overweight
Oct-18-21	Downgrade	BofA Securities	Neutral → Underperform
Apr-26-21	Resumed	Credit Suisse	Neutral
Mar-29-21	Upgrade	RBC Capital Mkts	Underperform → Sector Perform
Feb-12-21	Downgrade	BofA Securities	Buy → Neutral
Jan-05-21	Upgrade	Citigroup	Neutral → Buy
Nov-30-20	Downgrade	RBC Capital Mkts	Sector Perform → Underperform
Oct-30-20	Downgrade	Citigroup	Buy → Neutral
Oct-28-20	Initiated	UBS	Neutral
Oct-07-20	Upgrade	JP Morgan	Neutral → Overweight
Aug-25-20	Initiated	Raymond James	Outperform
Apr-09-20	Upgrade	Citigroup	Neutral → Buy
Feb-20-20	Downgrade	Citigroup	Buy → Neutral
Feb-20-20	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Nov-12-19	Initiated	SunTrust	Buy
May-13-19	Upgrade	BofA/Merrill	Neutral → Buy
Apr-11-19	Initiated	Bernstein	Outperform
Oct-03-18	Upgrade	BofA/Merrill	Underperform → Neutral
Oct-01-18	Initiated	Cantor Fitzgerald	Overweight
Jul-19-18	Initiated	Credit Suisse	Outperform
Jun-18-18	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Apr-04-18	Downgrade	Barclays	Equal Weight → Underweight
Jan-29-18	Resumed	RBC Capital Mkts	Sector Perform
Nov-16-17	Upgrade	JP Morgan	Underweight → Neutral
Oct-26-17	Downgrade	BofA/Merrill	Neutral → Underperform
Oct-09-17	Downgrade	JP Morgan	Neutral → Underweight

View All

Ptc Therapeutics Inc Stock (PTCT) Latest News

Aug 14, 2026

PTC Therapeutics Expands Rare Disease Portfolio with 'Unique Opportunity' - Sahm

Aug 14, 2026

PTCT Maintained by Barclays -- Price Target Raised to $122 - GuruFocus

Aug 14, 2026

Aug 13, 2026

PTC Therapeutics’ $211M Bid Wins Bankruptcy Auction for Sangamo Gene Therapy - MedCity News

Aug 13, 2026

PTCT Maintains Overweight Rating by Wells Fargo -- Price Target Raised to $109 - GuruFocus

Aug 13, 2026

PTC to Acquire Sangamo’s Fabry Disease Gene Therapy - Contract Pharma

Aug 13, 2026

PTC Therapeutics to Acquire ST-920 Fabry Gene Therapy - TipRanks

Aug 13, 2026

Form 8K PTC Therapeutics Inc For: 13 August By Investing.com - Investing.com Nigeria

Aug 13, 2026

PTC to expand rare disease portfolio with ST-920 buy - The Pharma Letter

Aug 13, 2026

PTC Therapeutics, Lilly to buy up bits of Sangamo in bankruptcy auction - Endpoints News

Aug 13, 2026

Aug 12, 2026